Share this article on:
Boston-based Life Biosciences Inc. has announced it has acquired the mobile communications platform developer Lua.
The move is part of the company’s plan to create a proprietary artificial intelligence (AI) platform which will help to accelerate research for new therapies, technologies, and pharmaceutical products to tackle age-related decline (ARD).
Biosciences Inc. will use Lua’s technology as the basis for a platform that allows comprehensive analyses of study data to be performed more quickly. The technology will also help to integrate scientific studies conducted at each of its daughter companies into a universal life Biosciences system more rapidly.
Lua was formed in 2010 with the aim of developing a mobile-first communications platform for use in healthcare to improve patient outcomes by removing the barriers to communication between providers and patients.
The communications platform includes a secure text messaging solution, supports voice and video calls, and allows files and medical images to be shared quickly and securely with all members of the care team. The improvements in efficiency allow healthcare professionals to spend more time treating patients, the patient experience is enhanced, and outcomes can be improved.
“We are excited to be joining the Life Biosciences family,” said Michael DeFranco, Co-founder and CEO of Lua. “Lua’s focus, to improve outcomes by streamlining access between healthcare providers and patients, fits perfectly with Life Biosciences’ mission to increase healthy lifespans for all. By creating real-time feedback loops, we expect to bring data-led insights to researchers in clinical trials that were not feasible earlier. We firmly believe our direct-to-consumer technology has the potential to change pet and ultimately human life as we know it.”